Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 40 entries
Sorted by: Best Match Show Resources per page
New Challenges in the Management of Diffuse Large B-Cell Lymphoma.

Treatment strategies. Hematology

Flowers CR, Nastoupil LJ, Bernal-Mizrachi L, Rose AC, Sinha R.
PMID: 23805376
Treat Strategies Hematol. 2012 Jan;2(1):68-73.

No abstract available.

Cite
Flowers CR, Nastoupil LJ, Bernal-Mizrachi L, et al. New Challenges in the Management of Diffuse Large B-Cell Lymphoma. Treat Strategies Hematol. 2012;2(1):68-73
Flowers, C. R., Nastoupil, L. J., Bernal-Mizrachi, L., Rose, A. C., & Sinha, R. (2012). New Challenges in the Management of Diffuse Large B-Cell Lymphoma. Treatment strategies. Hematology, 2(1), 68-73.
Flowers, Christopher R, et al. "New Challenges in the Management of Diffuse Large B-Cell Lymphoma." Treatment strategies. Hematology vol. 2,1 (2012): 68-73.
Flowers CR, Nastoupil LJ, Bernal-Mizrachi L, Rose AC, Sinha R. New Challenges in the Management of Diffuse Large B-Cell Lymphoma. Treat Strategies Hematol. 2012 Jan;2(1):68-73. PMID: 23805376; PMCID: PMC3690658.
Copy Download .nbib Format: NLM
Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms.

OncoTargets and therapy

Ludmir EB, Gutschenritter T, Pinnix CC, Gunther JR, Nastoupil LJ, Khoury JD, Medeiros LJ, Dabaja BS, Milgrom SA.
PMID: 30573980
Onco Targets Ther. 2018 Dec 10;11:8937-8942. doi: 10.2147/OTT.S159843. eCollection 2018.

Gastrointestinal stromal tumor (GIST) is an uncommon mesenchymal tumor, and has been shown to be associated with synchronous or metachronous second malignancies. Rare cases of coincident GIST and non-Hodgkin lymphomas (NHL) have been reported previously. Here, we report two...

Cite
Ludmir EB, Gutschenritter T, Pinnix CC, et al. Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms. Onco Targets Ther. 2018;11:8937-8942doi: 10.2147/OTT.S159843.
Ludmir, E. B., Gutschenritter, T., Pinnix, C. C., Gunther, J. R., Nastoupil, L. J., Khoury, J. D., Medeiros, L. J., Dabaja, B. S., & Milgrom, S. A. (2018). Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms. OncoTargets and therapy, 118937-8942. https://doi.org/10.2147/OTT.S159843
Ludmir, Ethan B, et al. "Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms." OncoTargets and therapy vol. 11 (2018): 8937-8942. doi: https://doi.org/10.2147/OTT.S159843
Ludmir EB, Gutschenritter T, Pinnix CC, Gunther JR, Nastoupil LJ, Khoury JD, Medeiros LJ, Dabaja BS, Milgrom SA. Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms. Onco Targets Ther. 2018 Dec 10;11:8937-8942. doi: 10.2147/OTT.S159843. eCollection 2018. PMID: 30573980; PMCID: PMC6292410.
Copy Download .nbib Format: NLM
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K.
PMID: 34724392
J Clin Oncol. 2021 Nov 01;JCO2101440. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 01.

PURPOSE: To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy.METHODS: A multidisciplinary panel of medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, neurology,...

Cite
Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;JCO2101440doi: 10.1200/JCO.21.01440.
Schneider, B. J., Naidoo, J., Santomasso, B. D., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Davies, M. J., Ernstoff, M. S., Fecher, L., Ghosh, M., Jaiyesimi, I., Mammen, J. S., Naing, A., Nastoupil, L. J., Phillips, T., Porter, L. D., Reichner, C. A., Seigel, C., Song, J. M., Spira, A., Suarez-Almazor, M., Swami, U., Thompson, J. A., Vikas, P., Wang, Y., Weber, J. S., Funchain, P., & Bollin, K. (2021). Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2101440. https://doi.org/10.1200/JCO.21.01440
Schneider, Bryan J, et al. "Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. (2021): JCO2101440. doi: https://doi.org/10.1200/JCO.21.01440
Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Nov 01;JCO2101440. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 01. PMID: 34724392.
Copy Download .nbib Format: NLM
A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.

Leukemia & lymphoma

Cherng HJ, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J.
PMID: 34435552
Leuk Lymphoma. 2021 Aug 26;1-10. doi: 10.1080/10428194.2021.1971223. Epub 2021 Aug 26.

Many patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will not respond to platinum-containing salvage chemotherapy. Predicting treatment failure earlier could help clinicians minimize chemotherapy toxicities for non-responders in favor of other treatments. We conducted a pilot...

Cite
Cherng HJ, Chuang HH, Steiner R, et al. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2021;1-10doi: 10.1080/10428194.2021.1971223.
Cherng, H. J., Chuang, H. H., Steiner, R., Fayad, L., Strati, P., Nair, R., Hagemeister, F., Nastoupil, L. J., Lee, H. J., Neelapu, S. S., Flowers, C. R., Samaniego, F., Rodriguez, M., Macapinlac, H. A., Feng, L., & Westin, J. (2021). A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leukemia & lymphoma, 1-10. https://doi.org/10.1080/10428194.2021.1971223
Cherng, Hua-Jay J, et al. "A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma." Leukemia & lymphoma vol. (2021): 1-10. doi: https://doi.org/10.1080/10428194.2021.1971223
Cherng HJ, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2021 Aug 26;1-10. doi: 10.1080/10428194.2021.1971223. Epub 2021 Aug 26. PMID: 34435552.
Copy Download .nbib Format: NLM
Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?.

EJHaem

Gunther JR, Pinnix CC, Glober GR, Christopherson KM, Fang P, Lee HJ, Ahmed S, Steiner RE, Nair R, Strati P, Neelapu SS, Nastoupil LJ, Dabaja BS.
PMID: 32864660
EJHaem. 2020 Jul;1(1):272-276. doi: 10.1002/jha2.1. Epub 2020 Feb 07.

Classical Hodgkin lymphoma (HL) patients achieve excellent outcomes; therefore, treatment de-escalation strategies to spare toxicity have been prioritized. In a large randomized trial of early stage HL patients, omission of chemotherapeutic agents including bleomycin from the standard ABVD (doxorubicin,...

Cite
Gunther JR, Pinnix CC, Glober GR, et al. Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?. EJHaem. 2020;1(1):272-276doi: 10.1002/jha2.1.
Gunther, J. R., Pinnix, C. C., Glober, G. R., Christopherson, K. M., Fang, P., Lee, H. J., Ahmed, S., Steiner, R. E., Nair, R., Strati, P., Neelapu, S. S., Nastoupil, L. J., & Dabaja, B. S. (2020). Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?. EJHaem, 1(1), 272-276. https://doi.org/10.1002/jha2.1
Gunther, Jillian R, et al. "Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?." EJHaem vol. 1,1 (2020): 272-276. doi: https://doi.org/10.1002/jha2.1
Gunther JR, Pinnix CC, Glober GR, Christopherson KM, Fang P, Lee HJ, Ahmed S, Steiner RE, Nair R, Strati P, Neelapu SS, Nastoupil LJ, Dabaja BS. Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?. EJHaem. 2020 Jul;1(1):272-276. doi: 10.1002/jha2.1. Epub 2020 Feb 07. PMID: 32864660; PMCID: PMC7455016.
Copy Download .nbib Format: NLM
Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy.

Frontiers in oncology

Fang PQ, Gunther JR, Wu SY, Dabaja BS, Nastoupil LJ, Ahmed S, Neelapu SS, Pinnix CC.
PMID: 33842363
Front Oncol. 2021 Mar 25;11:648655. doi: 10.3389/fonc.2021.648655. eCollection 2021.

CAR T-cell therapy has revolutionized the treatment approach to patients with relapsed/refractory hematologic malignancies; however, there continues to be opportunity for improvement in treatment toxicity as well as response durability. Radiation therapy can play an important role in combined...

Cite
Fang PQ, Gunther JR, Wu SY, et al. Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. Front Oncol. 2021;11:648655doi: 10.3389/fonc.2021.648655.
Fang, P. Q., Gunther, J. R., Wu, S. Y., Dabaja, B. S., Nastoupil, L. J., Ahmed, S., Neelapu, S. S., & Pinnix, C. C. (2021). Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. Frontiers in oncology, 11648655. https://doi.org/10.3389/fonc.2021.648655
Fang, Penny Q, et al. "Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy." Frontiers in oncology vol. 11 (2021): 648655. doi: https://doi.org/10.3389/fonc.2021.648655
Fang PQ, Gunther JR, Wu SY, Dabaja BS, Nastoupil LJ, Ahmed S, Neelapu SS, Pinnix CC. Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. Front Oncol. 2021 Mar 25;11:648655. doi: 10.3389/fonc.2021.648655. eCollection 2021. PMID: 33842363; PMCID: PMC8027336.
Copy Download .nbib Format: NLM
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, O'Hear C, Huang H, Kwan A, Li CC, Piccione EC, Wei MC, Yin S, Bartlett NL.
PMID: 34914545
J Clin Oncol. 2021 Dec 16;JCO2100931. doi: 10.1200/JCO.21.00931. Epub 2021 Dec 16.

PURPOSE: Mosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects T cells to engage and eliminate malignant B cells and is being developed for relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs).METHODS: This first-in-human trial (ClinicalTrials.gov identifier:...

Cite
Budde LE, Assouline S, Sehn LH, et al. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol. 2021;JCO2100931doi: 10.1200/JCO.21.00931.
Budde, L. E., Assouline, S., Sehn, L. H., Schuster, S. J., Yoon, S. S., Yoon, D. H., Matasar, M. J., Bosch, F., Kim, W. S., Nastoupil, L. J., Flinn, I. W., Shadman, M., Diefenbach, C., O'Hear, C., Huang, H., Kwan, A., Li, C. C., Piccione, E. C., Wei, M. C., Yin, S., & Bartlett, N. L. (2021). Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2100931. https://doi.org/10.1200/JCO.21.00931
Budde, Lihua E, et al. "Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. (2021): JCO2100931. doi: https://doi.org/10.1200/JCO.21.00931
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, O'Hear C, Huang H, Kwan A, Li CC, Piccione EC, Wei MC, Yin S, Bartlett NL. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol. 2021 Dec 16;JCO2100931. doi: 10.1200/JCO.21.00931. Epub 2021 Dec 16. PMID: 34914545.
Copy Download .nbib Format: NLM
Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews.

PharmacoEconomics - open

Monga N, Garside J, Gurung B, Quigley J, O'Donovan P, Tapprich C, Nastoupil L, Thieblemont C, Loefgren C.
PMID: 32200522
Pharmacoecon Open. 2020 Dec;4(4):575-591. doi: 10.1007/s41669-020-00204-z.

BACKGROUND: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are types of indolent non-Hodgkin lymphoma (NHL) that develop in the B lymphocytes (also known as B cells).OBJECTIVE: The aim of this study was to conduct a comprehensive review of...

Cite
Monga N, Garside J, Gurung B, et al. Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews. Pharmacoecon Open. 2020;4(4):575-591doi: 10.1007/s41669-020-00204-z.
Monga, N., Garside, J., Gurung, B., Quigley, J., O'Donovan, P., Tapprich, C., Nastoupil, L., Thieblemont, C., & Loefgren, C. (2020). Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews. PharmacoEconomics - open, 4(4), 575-591. https://doi.org/10.1007/s41669-020-00204-z
Monga, Neerav, et al. "Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews." PharmacoEconomics - open vol. 4,4 (2020): 575-591. doi: https://doi.org/10.1007/s41669-020-00204-z
Monga N, Garside J, Gurung B, Quigley J, O'Donovan P, Tapprich C, Nastoupil L, Thieblemont C, Loefgren C. Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews. Pharmacoecon Open. 2020 Dec;4(4):575-591. doi: 10.1007/s41669-020-00204-z. PMID: 32200522; PMCID: PMC7688753.
Copy Download .nbib Format: NLM
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma.

Head & neck

Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Yehia Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B.
PMID: 30990235
Head Neck. 2019 May;41(5):1546. doi: 10.1002/hed.25738. Epub 2019 Mar 19.

No abstract available.

Cite
Pinnix CC, Dabaja BS, Milgrom SA, et al. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2019;41(5):1546doi: 10.1002/hed.25738.
Pinnix, C. C., Dabaja, B. S., Milgrom, S. A., Smith, G. L., Abou Yehia, Z., Nastoupil, L., Romaguera, J., Turturro, F., Fowler, N., Fayad, L., Westin, J., Neelapu, S., Fanale, M. A., Rodriguez, M. A., Hagemeister, F., Lee, H. J., Oki, Y., Wang, M., Samaniego, F., Chi, L., & Esmaeli, B. (2019). Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head & neck, 41(5), 1546. https://doi.org/10.1002/hed.25738
Pinnix, Chelsea C, et al. "Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma." Head & neck vol. 41,5 (2019): 1546. doi: https://doi.org/10.1002/hed.25738
Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Yehia Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2019 May;41(5):1546. doi: 10.1002/hed.25738. Epub 2019 Mar 19. PMID: 30990235.
Copy Download .nbib Format: NLM
The evolving use of CAR T-cell therapy in follicular lymphoma.

Clinical advances in hematology & oncology : H&O

Nastoupil LJ.
PMID: 34807012
Clin Adv Hematol Oncol. 2021 Nov;19(11):684-686.

No abstract available.

Cite
Nastoupil LJ. The evolving use of CAR T-cell therapy in follicular lymphoma. Clin Adv Hematol Oncol. 2021;19(11):684-686
Nastoupil, L. J. (2021). The evolving use of CAR T-cell therapy in follicular lymphoma. Clinical advances in hematology & oncology : H&O, 19(11), 684-686.
Nastoupil, Loretta J. "The evolving use of CAR T-cell therapy in follicular lymphoma." Clinical advances in hematology & oncology : H&O vol. 19,11 (2021): 684-686.
Nastoupil LJ. The evolving use of CAR T-cell therapy in follicular lymphoma. Clin Adv Hematol Oncol. 2021 Nov;19(11):684-686. PMID: 34807012.
Copy Download .nbib Format: NLM
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma.

Leukemia & lymphoma

Nastoupil LJ, Neelapu SS, Davis RE, Samaniego F, Fowler NH, Westin J, Lee HJ, Wang M, Hagemeister F, Cecil ARL, Dow J, Haque K, Silva FA, Whale A, Lensun L, Bone EA, McElwaine-Johnn H, Beer PA.
PMID: 34365878
Leuk Lymphoma. 2021 Dec;62(14):3452-3462. doi: 10.1080/10428194.2021.1957874. Epub 2021 Aug 09.

PI3-kinase p110δ is mainly expressed in lymphocytes and is an attractive therapeutic target in B cell lymphomas. Targeting p110β may further suppress tumor growth and overcome escape mechanisms. KA2237 is an oral, potent, dual p110β/p110δ inhibitor. In preclinical studies,...

Cite
Nastoupil LJ, Neelapu SS, Davis RE, et al. Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma. Leuk Lymphoma. 2021;62(14):3452-3462doi: 10.1080/10428194.2021.1957874.
Nastoupil, L. J., Neelapu, S. S., Davis, R. E., Samaniego, F., Fowler, N. H., Westin, J., Lee, H. J., Wang, M., Hagemeister, F., Cecil, A. R. L., Dow, J., Haque, K., Silva, F. A., Whale, A., Lensun, L., Bone, E. A., McElwaine-Johnn, H., & Beer, P. A. (2021). Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma. Leukemia & lymphoma, 62(14), 3452-3462. https://doi.org/10.1080/10428194.2021.1957874
Nastoupil, Loretta J, et al. "Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma." Leukemia & lymphoma vol. 62,14 (2021): 3452-3462. doi: https://doi.org/10.1080/10428194.2021.1957874
Nastoupil LJ, Neelapu SS, Davis RE, Samaniego F, Fowler NH, Westin J, Lee HJ, Wang M, Hagemeister F, Cecil ARL, Dow J, Haque K, Silva FA, Whale A, Lensun L, Bone EA, McElwaine-Johnn H, Beer PA. Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma. Leuk Lymphoma. 2021 Dec;62(14):3452-3462. doi: 10.1080/10428194.2021.1957874. Epub 2021 Aug 09. PMID: 34365878.
Copy Download .nbib Format: NLM
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K.
PMID: 34724392
J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 01.

PURPOSE: To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy.METHODS: A multidisciplinary panel of medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, neurology,...

Cite
Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073-4126doi: 10.1200/JCO.21.01440.
Schneider, B. J., Naidoo, J., Santomasso, B. D., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Davies, M. J., Ernstoff, M. S., Fecher, L., Ghosh, M., Jaiyesimi, I., Mammen, J. S., Naing, A., Nastoupil, L. J., Phillips, T., Porter, L. D., Reichner, C. A., Seigel, C., Song, J. M., Spira, A., Suarez-Almazor, M., Swami, U., Thompson, J. A., Vikas, P., Wang, Y., Weber, J. S., Funchain, P., & Bollin, K. (2021). Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(36), 4073-4126. https://doi.org/10.1200/JCO.21.01440
Schneider, Bryan J, et al. "Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,36 (2021): 4073-4126. doi: https://doi.org/10.1200/JCO.21.01440
Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 01. PMID: 34724392.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 40 entries